per post by Markslempf on 3/30 (7:29 pm):
where you pontificated that you were doing us all a favor by suggesting that everyone should immediately sell the stock "before they lose all their money". Stock was at $17.69 on 3/30- now it is $23.71.
Your success or failure as a "trader" is not relevant to me. You are the sole master of your own destiny and quite candidly, I could care less whether you have been a winner or a loser.
There are so many stocks that fluctuate wildly on a daily basis. For example, I can't keep count of how many times in the last few weeks that CLF has traded daily between $2.95- $3.25 (10% daily swing) on heavy volume. If one is a trader, that is the type of stock to play. LCI would not be one that, in my opinion, fits that dynamic.
If you not a short then why make such consistently negative comments? No one disagrees that LCI has "issues" to overcome, but if you are truly long, it is illogical that you would continue to disseminate misinformation with the intent to "scare". .
Although I try to be civil to everyone, it is sometimes difficult to hold my tongue when dealing with people who take themselves far too seriously.
This is a social media posting board, nothing more. Why should anyone blow a fuse over what is posted? It is tantamount to "road rage". Scary!
Whether LCI has run out of steam is subject to debate. One thing that is clear is that you have plenty of hot air left.
Do you honestly believe that anyone cares what you post anymore? Give it a rest.
I was hoping it would not go lower then .50. I now feel that .40 is in the cards.
I keep averaging down and getting my butt handed to me.
I now understand. When it goes down you are short and when it goes up you are long. You can't lose with that ingenious strategy.
You are just too funny! Keep up the humorous posts.
Let's see- the stock was $17.89 at the close on 5/6/16. Now it is up a whopping 30% since that point while other pharmas have been flat.
Quite a brilliant assessment, Einstein!
This Order was issued based on the Application filed by the company in February. It is pretty standard in the industry in order to protect information.
There was no volume today so the move may be just a market order placed at the close. I hope there is more behind the move. We will see tomorrow morning g whether there is any follow through.
All patent rights have been assigned by Shaw to the company who is the exclusive licensee. That is why Shaw gets royalty payments and both were named plaintiffs in the litigation against BD.. As such, unless RVP defaults under the license agreement, the patents have no value to Shaw.
On April 26, 2016 Shaw and other individuals were issued a new patent (#9320469) for a retractable needle for blood gas sampling. This patent was also assigned to RVP.
My research has not detected any other similar product so it is possible that this patent has substantial value. With the IP, plant and real estate, the company should be worth at least $2/share.
what they reaped in compensation they lost several X more in stock price decline
small consolation for us
In the Politics section (page 10) of today's paper is an article written by Robert Pear titled " Proposal to Reduce Medicare Drug Payments is Widely Criticized". The article points out that most of the members of Congress are AGAINST the Obama administrations proposal to reduce Medicare payments for many prescription drugs. Patient advocates claim that the reductions could "jeopardize access to important medications".
Despite the scare tactics of our friendly neighborhood short players, the bottom line is that despite all the rhetoric by certain presidential candidates, there is considerable pressure to leave the present system intact and not to rock the boat. Lets face it, voters are more concerned with access to certain drugs then the price Medicare (or their insurance carrier) have to pay for them.
Our dysfunctional government and politicians, despite their god intentions, like to do a lot of talking but has little capacity to accomplish anything constructive. Believers in capitalism and competition will prevail as the market supply and demand will be most determinative of drug prices. Getting the gov't involved just makes matters worse for the consumer.
Management was the direct cause of the price plunge due to their aggregrious behavior in ignoring Privet's letter. They knew Privet would bail and they should have lined up a buyer to take the block.
Quite candidly, management has failed to perform and done virtually nothing to justify their large pay checks.
Reading the recent SEC filing, it appears that Shaw believes that sales will pick up justifying buying expensive new molding machines. So if you believe that the intrinsic value of the company is worth $2+, then when you factor in the litigation value you can easily conclude that the risks going forward are pretty nominal.